Last Updated: November 16, 2026

Details for Patent: RE49110

« Back to Dashboard


Which drugs does patent RE49110 protect, and when does it expire?

Patent RE49110 protects VRAYLAR and is included in one NDA.

Protection for VRAYLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in thirty-three countries.

Summary for Patent: RE49110
Title:Pharmaceutical formulations containing dopamine receptor ligands
Abstract:The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
Inventor(s):Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
Assignee: Richter Gedeon Nyrt
Application Number:US16/372,031
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE49110
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent RE49110

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-005 Dec 18, 2025 RX Yes No RE49110*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-006 Dec 18, 2025 RX Yes No RE49110*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes Yes RE49110*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-002 Sep 17, 2015 RX Yes No RE49110*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-003 Sep 17, 2015 RX Yes No RE49110*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-004 Sep 17, 2015 RX Yes No RE49110*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE49110

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2975 ⤷  Start Trial
Australia 2009270823 ⤷  Start Trial
Brazil PI0916241 ⤷  Start Trial
Canada 2730287 ⤷  Start Trial
Chile 2011000091 ⤷  Start Trial
China 102118970 ⤷  Start Trial
China 104997743 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.